Gastrointestinal Drugs Advisory Committee

Although Ocaliva in primary biliary cholangitis (PBC) has received the backing of an FDA panel, the panel did not endorse the drug for use in patients with advanced PBC, while recommending restrictions for use in non-responders and cirrhotics due to concerns regarding liver toxicity and safety....